Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miso Kim

Showing results (131-140 of 184) with videos related to

Pageof 19
Sort By:
Scientific Reports|January 29, 2021
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patientsJa Yoon Heo, Shin Hye Yoo, Koung Jin Suh, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2019
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancerSehui Kim, Ji-Young Jang, Jaemoon Koh, et al.
World Journal of Gastroenterology|October 13, 2016
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinomaRyul Kim, Bhumsuk Keam, Dohee Kwon, et al.
Leukemia & Lymphoma|May 10, 2017
Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experienceJa Min Byun, Ki Hwan Kim, Miso Kim, et al.
Cancer|October 27, 2021
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)Hongsik Kim, Dong-Wan Kim, Miso Kim, et al.
Translational Lung Cancer Research|March 15, 2021
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinomaMinsu Kang, Changhee Park, Se Hyun Kim, et al.
Korean Circulation Journal|December 18, 2019
Novel Associations between Related Proteins and Cellular Effects of High-Density LipoproteinSeungbum Choi, Yae Eun Park, Eun Jeong Cheon, et al.
BMC Cancer|January 9, 2019
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitorsRyul Kim, Bhumsuk Keam, Sehui Kim, et al.
Cancer Research and Treatment|September 25, 2020
Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer PatientsMihong Choi, Jiyeon Han, Bo Ram Yang, et al.
Genes & Genomics|May 26, 2020
A newly developed capture-based sequencing panel for genomic assay of lung cancerSun-Wha Im, Jeesoo Chae, Se Song Jang, et al.
Pageof 19

Showing results (131-140 of 184) with videos related to

Sort By:
Pageof 19
Scientific Reports|January 29, 2021
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patientsJa Yoon Heo, Shin Hye Yoo, Koung Jin Suh, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2019
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancerSehui Kim, Ji-Young Jang, Jaemoon Koh, et al.
World Journal of Gastroenterology|October 13, 2016
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinomaRyul Kim, Bhumsuk Keam, Dohee Kwon, et al.
Leukemia & Lymphoma|May 10, 2017
Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experienceJa Min Byun, Ki Hwan Kim, Miso Kim, et al.
Cancer|October 27, 2021
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)Hongsik Kim, Dong-Wan Kim, Miso Kim, et al.
Translational Lung Cancer Research|March 15, 2021
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinomaMinsu Kang, Changhee Park, Se Hyun Kim, et al.
Korean Circulation Journal|December 18, 2019
Novel Associations between Related Proteins and Cellular Effects of High-Density LipoproteinSeungbum Choi, Yae Eun Park, Eun Jeong Cheon, et al.
BMC Cancer|January 9, 2019
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitorsRyul Kim, Bhumsuk Keam, Sehui Kim, et al.
Cancer Research and Treatment|September 25, 2020
Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer PatientsMihong Choi, Jiyeon Han, Bo Ram Yang, et al.
Genes & Genomics|May 26, 2020
A newly developed capture-based sequencing panel for genomic assay of lung cancerSun-Wha Im, Jeesoo Chae, Se Song Jang, et al.
Pageof 19